DDInter130 DDInter1376
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Atenolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Atenolol {u} (Compound) resembles {v} (Compound) Chlorphenesin
Atenolol {u} (Compound) binds {v} (Gene) ADRB2
Atenolol {u} (Compound) upregulates {v} (Gene) UBQLN2
Atenolol {u} (Compound) causes {v} (Side Effect) Dry mouth
Atenolol (Compound) resembles Oxprenolol (Compound)
Atenolol (Compound) resembles Chlorphenesin (Compound)
Atenolol (Compound) binds ADRB2 (Gene)
Atenolol (Compound) upregulates UBQLN2 (Gene)
Atenolol (Compound) causes Dry mouth (Side Effect)